IFNA1 and COVID-19: Notably, use of recombinant IFN-β as a therapeutic for COVID-19 has shown promise in some trials, but not others [155,156,157], and a retrospective study described that early treatment of COVID-19 patients with IFN-α decreased mortality while late treatment resulted in the opposite outcome [158].